


Journal Pre-proof

Protein arginine methyltransferase 1 contributes to the development of allergic rhinitis by promoting the production of epithelial-derived cytokines

Ji-Yeon Park, BS, Joo-Hee Choi, PhD, Sang-Nam Lee, PhD, Hyung-Ju Cho, MD, PhD, Ji-Suk Ahn, BS, Yong-Bum Kim, PhD, Do-Yong Park, MS, Sang-Chul Park, MD, PhD, Soo-In Kim, MS, Min-Jung Kang, PhD, Ah-Ra Jang, BS, Jae-Hun Ahn, DVM, Tae-Sung Lee, DVM, Dong-Yeon Kim, DVM, Sung Jae Shin, DVM, PhD, Joo-Heon Yoon, MD, PhD, Jong-Hwan Park, DVM, PhD



PII: S0091-6749(21)00045-2

DOI: <https://doi.org/10.1016/j.jaci.2020.12.646>

Reference: YMAI 14928

To appear in: *Journal of Allergy and Clinical Immunology*

Received Date: 23 June 2020

Revised Date: 5 November 2020

Accepted Date: 8 December 2020


Please cite this article as: Park J-Y, Choi J-H, Lee S-N, Cho H-J, Ahn J-S, Kim Y-B, Park D-Y, Park S-C, Kim S-I, Kang M-J, Jang A-R, Ahn J-H, Lee T-S, Kim D-Y, Shin SJ, Yoon J-H, Park J-H, Protein arginine methyltransferase 1 contributes to the development of allergic rhinitis by promoting the production of epithelial-derived cytokines, *Journal of Allergy and Clinical Immunology* (2021), doi: <https://doi.org/10.1016/j.jaci.2020.12.646>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.



PRMT1 contributes to the development of allergic rhinitis by promoting the production of epithelial-derived cytokines



Protein arginine methyltransferase 1 contributes to the development of allergic rhinitis by promoting the production of epithelial-derived cytokines

Ji-Yeon Park, BS^a, Joo-Hee Choi, PhD^a, Sang-Nam Lee, PhD^b, Hyung-Ju Cho, MD, PhD^c, Ji-Suk Ahn, BS^b, Yong-Bum Kim, PhD^d, Do-Yong Park, MS^d, Sang-Chul Park, MD, PhD^c, Soo-In Kim, MS^e, Min-Jung Kang, PhD^a, Ah-Ra Jang, BS^a, Jae-Hun Ahn, DVM^a, Tae-Sung Lee, DVM^a, Dong-Yeon Kim, DVM^a, Sung Jae Shin, DVM, PhD^f, Joo-Heon Yoon, MD, PhD^{b,c*}, Jong-Hwan Park, DVM, PhD^{1a*}

^aLaboratory Animal Medicine, College of Veterinary Medicine and Animal Medical Institute, Chonnam National University, Gwangju, Republic of Korea

^bThe Airway Mucus Institute, Yonsei University College of Medicine, Seoul, Republic of Korea

^cDepartment of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Republic of Korea

^dCenter for Nonclinical Studies, Korea Institute of Toxicology, Daejeon, Republic of Korea

^eThe Research Center for Human Natural Defense System, Yonsei University College of Medicine, Korea

^fDepartment of Microbiology, Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Republic of Korea

Running title: Role of PRMT1 in allergic rhinitis

*Correspondence to: Dr. Joo-Heon Yoon, Department of Otorhinolaryngology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea

Tel.: +82-2-228-3610, Fax: +82-2-393-0580, E-mail: jhyoon@yuhs.ac

Jong-Hwan Park, DVM and Ph.D.

Laboratory Animal Medicine, College of Veterinary Medicine, Chonnam National University, 77 Yongbong-ro, Buk-gu, Gwangju 61186, Republic of Korea

Tel.: +82-62-530-2834, Fax: +82-62-530-2809, E-mail: jonpark@jnu.ac.kr

Funding

This research was supported by the Global Research Lab (GRL) Program (Grant No. 2016K1A1A2910779) and the Mid-Career Researcher Program (Grant No. 2018R1A2B3004143) of the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (Information and Communication Technologies).

Conflict of interest

The authors have no financial conflicts of interest.

Abstract

Background: Arginine methylation is a posttranslational modification mediated by protein arginine methyltransferases (PRMTs). Although previous studies have shown that PRMT1 contributes to the severity of allergic airway inflammation or asthma, the underlying mechanism is poorly understood.

Objective: This study aimed to explore the role of PRMT1 and its relevant mechanism in the development of AR.

Methods: The expression levels of PRMTs and cytokines were determined by RT-PCR, and the localization of PRMT1 was determined by immunohistochemistry and confocal microscopy. The levels of house dust mite (HDM)-specific immunoglobulins in serum and of cytokines in nasal lavage fluids were determined by ELISA. PRMT1 inhibition was achieved by siRNA and treatment with the pan PRMT inhibitor arginine N-Methyltransferase Inhibitor-1 (AMI-1).

Results: PRMT1 expression was significantly increased in the nasal mucosa of patients and mice with AR. The degree of eosinophilic infiltration in the nasal mucosa was reduced in *PRMT1*^{+/-} AR mice compared with wild-type (WT) mice. PRMT1 haploinsufficiency reduced the levels of HDM-specific immunoglobulins in serum and those of Th2 (IL-4, IL-5, and IL-13) and epithelial (TSLP, IL-25, and IL-33) cytokines in the nasal lavage fluids of AR mice. In nasal epithelial cells, HDM and IL-4 cooperate to enhance PRMT1 expression through a mitogen-activated protein kinase (MAPK)-dependent pathway. In addition, PRMT1 was essential for the production of TSLP, IL-25, and IL-33 in response to HDM and IL-4. AMI-1 treatment alleviated AR in the mouse model.

Conclusion: PRMT1 plays an important role in AR development by regulating epithelial-derived

cytokine production and might be a new therapeutic target for AR.

Key messages

- PRMT1 expression is upregulated in the nasal mucosa of patients and mice with AR.
- HDM and IL-4 cooperate to induce PRMT1 expression via MAPKs signaling.
- PRMT1 inhibition alleviates the disease severity in AR mice.

Capsule summary

Antigens and IL-4 cooperate to upregulate PRMT1 expression in nasal epithelial cells, which results in increased TSLP, IL-25, and IL-33 production. These epithelial-derived cytokines contribute to AR development by promoting the differentiation into Th2 cytokines-producing cells

Key words: PRMT1, allergic rhinitis (AR), epithelial cytokines, MAPKs, house dust mite (HDM)

Abbreviations

AR: Allergic rhinitis

PRMTs: Protein arginine methyltransferases

ADMA: Asymmetric dimethylarginine

SDMA: Symmetric dimethylarginine

EGFR: Epidermal growth factor receptor

- 89 COPD: Chronic obstructive pulmonary disease
- 90 AIPI: Antigen-induced pulmonary inflammation
- 91 COX2: Cyclooxygenase-2
- 92 HDM: House dust mite
- 93 AMI-1: Arginine N-Methyltransferase Inhibitor-1
- 94 WT: Wild-type
- 95 MAPKs: Mitogen-activated protein kinases
- 96 NAL: Nasal lavage
- 97 HNECs: Human primary nasal epithelial cells
- 98 ALI: Air-liquid interface
- 99 RT-PCR: Real-time quantitative polymerase chain reaction
- 100 SDS-PAGE: Sodium dodecyl sulfate polyacrylamide gel electrophoresis
- 101 H&E: Hematoxylin & eosin
- 102 ILC2: Innate lymphoid cell 2
- 103 IPF: Idiopathic pulmonary fibrosis
- 104 PDGF: Platelet-derived growth factor
- 105 GC: Germinal center
- 106 AB/PAS: Alcian blue/periodic acid-Schiff

Introduction

Allergic rhinitis (AR) is an upper airway disease caused by the IgE-mediated immune response of the nasal mucosa to environmental allergen exposure.¹ This disease affects 10-40% of the population worldwide, and its prevalence has increased rapidly over the last few decades.² AR can lead to nasal symptoms, such as sneezing, itching, runny nose, rhinorrhea, nasal congestion, and watery eyes, which can have significantly negative effects on quality of life and daily function and cause sleep disturbances and emotional problems.³ Despite this high incidence and risk, the current therapies for AR are inadequate for some patients; 1) who have an eosinophil-dominant allergic nasal polyp or rhinitis⁴ 2) who has a high level of serum IgE or blood eosinophils,⁵ or 3) who are inevitably exposed to high amounts of causal allergens during a season or at a working place, and no appropriate remedy or medicine is available.

Protein arginine methyltransferases (PRMTs) mediate the arginine methylation of proteins, which is a novel posttranslational modification.^{6, 7} This process contributes to multiple cellular events, including transcriptional regulation, signal transduction, chromatin structure, and DNA damage repair.^{8, 9} Based on the end products, PRMTs are classified into several families. Type I PRMTs include PRMT1, 2, 3, 4, 6 and 8, which are involved in the production of asymmetric dimethylarginine (ADMA). In contrast, type II PRMTs, such as PRMT5 and 9, generate symmetric dimethylarginine (SDMA).¹⁰ Among these, PRMT1 produces 90% of the generated ADMA.¹¹ DNA methylation and histone alterations play critical roles in cancer development, and PRMT1 is overexpressed in various human cancers.¹² In addition, arginine methylation by PRMT1 plays an important role in lung diseases, such as pulmonary fibrosis and chronic

obstructive pulmonary disease (COPD), as well as lung cancer.¹³ However, the role of PRMTs in the development of allergic diseases is limited.

Some studies have shown that PRMT1 contributes to antigen-induced pulmonary inflammation and allergic asthma.¹⁴⁻¹⁶ PRMT1-3 expression in the lungs is upregulated in E3 rats with antigen-induced pulmonary inflammation (AIP), and IL-4 leads to increased expression of PRMT1 in lung epithelial cells at an early stage of inflammation.¹⁶ In contrast, at the chronic phase of AIP, PRMT1 expression is upregulated mainly in fibroblasts and smooth muscle layers but not in airway epithelial cells.¹⁵ TGF- β is responsible for the upregulation of PRMT1 and cyclooxygenase-2 (COX2) in fibroblasts, and the blockage of PRMTs using arginine N-Methyltransferase Inhibitor-1 (AMI-1), a pan PRMT inhibitor, reduces COX2 expression and asthmatic indexes in chronic AIP-induced rats.¹⁵ In addition, PRMT1 is constitutively and highly expressed in asthmatic airway smooth muscle cells, and this upregulation contributes to tissue remodeling by regulating cell proliferation and extracellular matrix production.¹⁴ These findings demonstrate an association between arginine methylation and the development of allergic diseases, but the expression of PRMTs in the nasal mucosa and the role of PRMTs in AR development have not been studied. In the present study, we found that PRMT1 expression is upregulated in the nasal mucosa of patients with AR and a mouse model of AR. PRMT1 deficiency or inhibition alleviates allergic inflammation in the nasal mucosa of mice. In addition, HDM and IL-4 synergistically induce PRMT1 expression in nasal epithelial cells and thereby regulate the production of TSLP, IL-25, and IL-33, which are cytokines critical for Th2 cell differentiation.

Methods

Wild-type (WT) C57BL/6 mice and PRMT1-haploinsufficient (*PRMT1*^{+/-}) mice had AR induced using HDM as depicted in Fig E1. The gene expression of PRMTs was analyzed by RT-PCR in human and mouse nasal tissue. The localization of PRMT1 was determined by immunohistochemistry and confocal microscopy. The degree of mucus secretion was examined by AB/PAS staining, and the degree of eosinophil infiltration was assessed by Sirius red staining as previously.¹⁷ The antigen-specific immunoglobulin levels in serum and cytokine levels in nasal lavage fluids or cell culture supernatants were measured by ELISA. In RPMI 2650 cells, the level of PRMT1 was determined by Western blotting and immunofluorescence. PRMT1 inhibition was achieved by siRNA and treatment with the pan PRMT inhibitor AMI-1. The complete and detailed methods are available in this article's Online Repository at www.jacionline.org.

Results

Expression of PRMT1 is upregulated in the nasal mucosa of patients with AR and AR mouse models

We first compared the gene expression of PRMTs in the nasal mucosa of non-AR controls and patients with AR. Among type I PRMTs, the PRMT1 and PRMT4 gene expression levels were significantly upregulated in the nasal mucosa of AR patients compared with that of the control group (Fig 1, A and C), whereas neither PRMT3 nor PRMT5 showed significant differences in gene expression (Fig 1, B and D).

We further examined PRMTs expression in the nasal mucosa of HDM-induced AR mice (Fig E1). The gene expression of PRMT1 was significantly increased in the nasal mucosa of HDM-induced AR mice compared with that of the control mice (Fig 2, A). Consistent with the results obtained with the human samples, PRMT3 and PRMT5 expression in the nasal mucosa was comparable between the control and AR-induced mice (Fig 2, B and D). The mean expression level of PRMT4 was slightly higher in the AR-induced mice, but no significant difference in its expression level was found between the control and AR-induced mice (Fig 2, C). An immunohistochemistry analysis was also performed to demonstrate the presence and localization of PRMT1 in nasal tissues of AR-induced mice (Fig 2, E). When reacted with isotype IgG, no positive signal was found in the nasal tissues of mice with AR (Fig 2, E). PRMT1 was moderately expressed in the nuclei of nasal epithelial and stromal cells in PBS-treated or HDM-immunized mice (Fig 2, E and F), whereas very weak expression of PRMT1 was found in the cytoplasm of these cells (Fig 2, E). However, strong and moderate PRMT1 expression was observed in the nucleus and cytoplasm, respectively, of nasal epithelial cells of HDM-challenged

AR mice (Fig 2, *E* and *F*). In Western blot analysis, PRMT1 protein strongly detected in nasal mucosa of AR mice, but not in control mice (Fig 2, *G* and *H*). These results show that PRMT1 expression is upregulated in nasal tissues with AR, which indicates that PRMT1 might play a role in the development of AR.

PRMT1 deficiency suppresses the development of AR in HDM-challenged mice

PRMT1-haploinsufficient mice ($PRMT1^{+/-}$) were used to determine the role of PRMT1 on the development of AR *in vivo* because mice with a homozygous allele of hypomorphic PRMT1 exhibit embryonic lethality.¹⁸ Lower PRMT1 gene expression was detected in the nasal tissue of $PRMT1^{+/-}$ mice compared with that of wild-type (WT) mice (Fig E2). The analysis of AB/PAS-stained sections revealed increased numbers of mucus-secreting cells in the nasal mucosa of HDM-challenged WT mice, whereas lower numbers were found in $PRMT1^{+/-}$ mice (Fig 3, *A* and *B*). In addition, Sirius red staining revealed that HDM challenge led to massive eosinophil infiltration in the nasal mucosa of WT mice, whereas a lower eosinophilic infiltration score was given to $PRMT1^{+/-}$ mice (Fig 3, *A* and *C*).

IgE is a critical factor for the development of allergic diseases because it promotes the production of inflammatory mediators such as histamine, prostaglandins, and cytokines in mast cells.¹⁹ Therefore, we examined the involvement of PRMT1 in the production of HDM-specific antibodies, including IgE. The serum level of HDM-specific IgE after HDM challenge was significantly higher in WT mice than in $PRMT1^{+/-}$ mice (Fig 3, *D*). Moreover, the levels of the IgM, IgG, and IgG subclasses (IgG1, IgG2c, and IgG2b) specific to HDM were also higher in WT mice than in $PRMT1^{+/-}$ mice (Fig 3, *E-I*). These findings indicate that PRMT1 contributes to the development of AR by promoting Ag-specific IgE production.

PRMT1 regulates Th2 cytokine production in nasal lavage fluids of mice with AR

Because Th2 cytokines, such as IL-4, IL-5, and IL-13, are responsible for IgE production by B cells, the activation and recruitment of eosinophils, and mucus production,²⁰ we further investigated whether PRMT1 contributes to the cytokines production. HDM challenge increased the production of IL-4, IL-5, and IL-13 in NAL fluids, and the levels in *PRMT1*^{+/-} mice were significantly lower than those in WT mice (Fig 4, A-C). The levels of IFN- γ and IL-17 in NAL fluids were also increased by HDM challenge, but comparable levels were detected in WT and *PRMT1*^{+/-} mice (Fig E3). Because the epithelial production of TSLP, IL-25, and IL-33 is essential for Th2 or innate lymphoid cell 2 (ILC2) differentiation,²¹ the cytokine levels were also determined. Substantial levels of TSLP, IL-25, and IL-33 were detected in NAL fluids of HDM-challenged WT mice, and the levels in *PRMT1*^{+/-} mice were significantly lower (Fig 4, D-F). It is likely that PRMT1 participates in the allergen-mediated production of Th2 cytokines through upregulation of the epithelial production of TSLP, IL-25, and IL-33.

HDM and rIL-4 synergistically enhance PRMT1 expression in human nasal epithelial cells through MAPK-dependent pathways

HDM extract can activate nasal epithelial cells and enhance the expression of various genes.²²⁻²⁴ In addition, IL-4 produced by Th2 cells upregulates PRMT1 gene expression in respiratory epithelial cells via a positive feedback loop.¹⁶ To determine a molecular mechanism underlying the enhancement of PRMT1 expression in a human nasal epithelial cell line, RPMI 2650 cells were treated with HDM and/or rIL-4. Treatment with HDM or rIL-4 alone slightly increased the gene and protein expression of PRMT1 in RPMI 2650 cells, and their combination markedly

enhanced its expression compared with that in cells treated with HDM or rIL-4 alone (Fig 5, A-C). We further determined the localization of PRMT1 in HDM/rIL-4-treated cells because its localization differs depending on the disease and cell type.²⁵⁻²⁸ Confocal microscopy showed that the nuclear expression of PRMT1 in the cells was enhanced by HDM/rIL-4 treatment (Fig 5, D and E). In addition, HDM/rIL-4 treatment enhanced ADMA formation in nasal epithelial cells (Fig 5, F). Because mitogen-activated protein kinases (MAPKs) are known to be involved in the regulation of PRMT1 expression,^{14, 29, 30} we assessed whether HDM/rIL-4 treatment influences MAPK activation in RPMI 2650 cells. HDM-and-rIL-4 cotreatment slightly enhanced the phosphorylation of ERK and p38 starting at 30 min and more strongly promoted JNK phosphorylation starting at 15 min (Fig 5, G). PD98059 (an ERK inhibitor) and SB203580 (a p38 inhibitor) suppressed the HDM-and-rIL-4-mediated increase in PRMT1 expression (Fig 5, H and I). The JNK inhibitor SP600125 also downregulated the expression of PRMT1 to the level found in untreated cells (Fig 5, H and I). The HDM/rIL-4-induced nuclear expression of PRMT1 was also reduced by MAPK inhibitors (Fig 5, J and K). These findings indicate that HDM and rIL-4 might cooperate to increase PRMT1 expression and promote its nuclear localization through the MAPK pathway, particularly JNK-dominant signaling, in nasal epithelial cells.

PRMT1 mediates the expression of TSLP, IL-25, and IL-33 in nasal epithelial cells in response to HDM and rIL-4

PRMT1 regulates gene transcription and protein activity by catalyzing the methylation of histones and cellular proteins.¹⁰ To determine whether PRMT1 regulates the expression of TSLP, IL-25, and IL-33 in nasal epithelial cells, PRMT1 expression in RPMI 2650 cells was inhibited by siRNA, and the cells were subsequently treated with HDM and rIL-4. siRNA successfully

reduced the gene and protein expression of PRMT1 in the cells (Fig E4, A and B). Cotreatment with HDM and rIL-4 enhanced the gene expression of TSLP, IL-25, IL-33 and eotaxin-1 in RPMI 2650 cells, and this enhancement was not detected in the cells in which PRMT1 was inhibited by siRNA (Fig 6, A, and Fig. E4, C). In contrast, PRMT1 inhibition by siRNA did not influence gene expression of MUC5AC, MUC5B, CXCL1, and CCL2 upregulated by cotreatment with HDM and rIL-4 (Fig. E4, D-G). To confirm the occurrence of this phenomenon under more physiological conditions, human primary nasal epithelial cells (hNECs) were prepared under air-liquid interface (ALI) culture conditions. Consistently, the PRMT1 expression was upregulated in hNECs after treatment with HDM and rIL-4 (Fig 6, B). AMI-1 treatment reduced the HDM-and-rIL-4-induced enhancement of TSLP, IL-25, IL-33, and eotaxin-1 gene expression in hNECs (Fig 6, C, and Fig. E4, D). During culture for 3 days, the production of TSLP in the culture supernatant was increased by HDM and rIL-4 treatment, and this increase was partially inhibited by AMI-1 (Fig 6, D). IL-25 and IL-33 protein expression was undetectable in this system (data not shown). These findings indicate that PRMT1 might contribute to the development of AR by regulating the production of TSLP, IL-25, and IL-33 in nasal epithelial cells in response to allergen and IL-4.

AMI-1 treatment alleviates HDM-induced AR in mice

We subsequently sought to determine whether the pharmacological inhibition of PRMT1 alleviates AR development *in vivo*. The pan PRMT inhibitor AMI-1 was i.p. given to the mice before and after HDM challenge in accordance to the experimental schedule depicted in Fig 7A. As shown in Fig 7B-D, AMI-1 treatment reduced the infiltration of mucus-secreting cells and eosinophils in the nasal mucosa of AR-induced mice. AMI-1 treatment also decreased the

279 production of immunoglobulins tested, except IgG2c, in serum (Fig 7, *E*, and Fig E5). In NAL
280 fluids, the production of IL-4 was also decreased by AMI-1 treatment (Fig 7, *F*). The mean
281 levels of IL-5 and IL-13 in NAL fluids were also decreased by treatment with AMI-1, but this
282 decrease was not significant (Fig 7, *F*). The levels of TSLP, IL-25, and IL-33 in NAL fluids were
283 also lower in the AMI-treated mice (Fig 7, *G*).

Discussion

Although PRMT1 is involved in the pathophysiology of various diseases, including chronic pulmonary inflammation, the role of PRMT1 in the development of AR has not been studied. In the present study, we revealed that PRMT1 expression was upregulated in the nasal mucosa of patients and mice with AR and that PRMT1 deficiency or inhibition reduced eosinophil infiltration in the nasal mucosa and the production of Ag-specific immunoglobulins, including IgE, and Th2 cytokines, such as IL-4, IL-5, and IL-13, in serum. PRMT1 was also essential for TSLP, IL-25, and IL-33 production in nasal epithelial cells in response to HDM and IL-4.

Aberrant expression of PRMTs, mainly their overexpression, appears to be associated with the development of several diseases. PRMT1 overexpression has been detected in various cancers, such as lung, breast, prostate, colon, and bladder cancers.⁸ During osteoclastogenesis, RANKL upregulates PRMT1 expression in bone marrow cells, which is critical for NF- κ B activation and osteoclastogenesis-related gene expression.²⁹ Moreover, an association between increased PRMT1 expression and allergic airway inflammation has been found. E3 rats with AIPI exhibited increased PRMT1, 2, and 3 expression and lower PRMT4 expression in the lungs compared with control mice.¹⁶ The expression of PRMT5 and PRMT6 appears to be unaffected.¹⁶ In the present study, PRMT1 and PRMT4 expression was upregulated in the nasal mucosa of AR patients. In addition, PRMT1 was also significantly increased in the nasal mucosa of HDM-induced AR mice compared with that of the control mice. Although no significant difference in PRMT4 expression was found between the two groups, its mean level was slightly higher in the nasal mucosa of AR mice. This finding is inconsistent with the results of a previous

study conducted by Sun et al.,¹⁶ which found lower expression of PRMT4 in the lung tissue of E3 rats with AIPI. Whether this discrepancy is due to differences in tissue origin remains unclear. In the present study, we investigated the role of PRMT1 in AR development because PRMT1 is overexpressed in the nasal mucosa of both humans and mice with AR and is responsible for >90% of ADMA formation.¹¹ Whether PRMT4 contributes to AR development should thus be clarified.

A previous study showed that PRMT1 is mostly expressed in epithelial cells at the acute phase of AIPI, whereas its expression is strongly detected in fibroblasts or smooth muscle cells, but not epithelial cells, at the chronic phase.¹⁵ In addition, PRMT1 is more highly expressed in airway smooth muscle cells from asthmatic patients compared with healthy controls,¹⁴ which suggests that PRMT1 can be expressed in various cell types in the respiratory tract. In this study, strong expression of PRMT1 was mostly observed in the nucleus of nasal epithelial cells in both humans and mice with AR, although its nuclear expression was also observed in inflammatory and stromal cells. Moreover, the experimental schedule of the HDM-induced AR mouse model is similar to that of the acute AIPI model.¹⁵ These findings suggest that PRMT1 might play an important role in nasal epithelial cells during AR development, at least at the acute phase.

In our data, four of 10 patients in the AR group had a low level of PRMT1, but there was no significant difference in eosinophil count or total IgE level among AR patients. Interestingly, we realized that the three of them were non-smoker and another patient was a short-term (10 < pack-years) smoker, whereas most AR patients with a high level of PRMT1 were more than ten pack-years of ex-smoker or current long-term smokers. In airway epithelial cells, only a small overlap in DNA methylation is observed with whole blood and magnitude of changes is about 10 times

larger than what was seen in the peripheral blood,³¹⁻³³ suggesting specific targets in airway epithelial cells. In addition, COPD is usually related to tobacco smoking and develops in mid to later life, and arginine methylation by PRMT1 was suggested to play an essential role in COPD.¹³ Therefore, our data suggest that smoking history seems to be a factor influencing PRMT1 levels.

PRMT1 can be localized in both the nucleus and cytoplasm and shows high mobility between both regions depending on the methylation status of the substrate proteins in several cells.³⁴ This shuttling controls the processes of signal transduction, subcellular protein trafficking, and gene expression.^{34, 35} In normal and cancerous tissues of the breast and colon, PRMT1 staining is mostly detected in the cytoplasm and is rarely detected in the nucleus.^{26, 27} The researchers of these previous studies claim that the enzyme is likely localized in the cytoplasm because methylation might occur during or just after translation.^{26, 27} In contrast, PRMT1 expression is mostly found in the nucleus of gastric cancer tissues, which is associated with poor diagnosis.²⁵ In lung fibroblasts isolated from idiopathic pulmonary fibrosis (IPF) patients, PRMT1 is predominantly localized in the nucleus and moderately expressed in the cytoplasm.²⁸ In the present study, we found strong PRMT1 expression in the nuclei of nasal epithelial cells of patients and mice with AR, although weak to moderate PRMT1 expression was still observed in the cytoplasm. Moreover, confocal microscopy observations showed that the nuclear expression of PRMT1 in RPMI 2650 cells was enhanced in response to HDM and rIL-4 and thus supported this hypothesis. The identities of the genes or proteins that enhance PRMT1 regulation in the nucleus of nasal epithelial cells remain to be elucidated.

Previous studies have shown that IL-4 promotes PRMT1 expression in lung fibroblasts and airway epithelial cells.^{16, 28} In the present study, IL-4 also upregulated the gene and protein expression of PRMT1 in nasal epithelial cells. Interestingly, HDM synergized with IL-4 to enhance PRMT1 expression and its nuclear localization in the cells, which suggests that allergens might cooperate with IL-4 to regulate PRMT1 expression. MAPK family members, such as ERK, JNK, and p38, play a central role in mediating multiple signaling pathways involved in inflammation, immunity, and cell survival. MAPKs have been shown to regulate PRMT1 expression under various experimental conditions. Lim et al.³⁰ showed that hypoxia-induced PRMT1 expression is downregulated by inhibitors of p38 and JNK, but not ERK, in human lung epithelial cells. Platelet-derived growth factor (PDGF) induces ERK phosphorylation in airway smooth muscle cells and thereby regulates PRMT1 expression.¹⁴ In addition, RANKL treatment promotes PRMT1 expression in bone marrow cells through a JNK-dependent pathway, which is essential for osteoclastogenesis.²⁹ In this study, we showed that cotreatment with HDM and rIL-4 induces the phosphorylation of all MAPKs (p38, ERK, and JNK) with different kinetics and to different degrees in RPMI 2650 cells. Each inhibitor can reduce HDM/rIL-4-induced PRMT1 expression, and in the presence of a JNK inhibitor, the expression level reached almost basal levels, which suggests that the MAPK pathway with JNK dominancy might be essential for regulating PRMT1 expression in nasal epithelial cells.

Protein arginine methylation might play unique roles in humoral immune responses, including B cell proliferation, differentiation, and survival. Hata and Mizuguchi detected reduced proliferation of B cells and decreased differentiation of these cells into IgG1-secreting cells in the presence of arginine methyltransferase inhibitor after stimulation with LPS/IL-4/CD40-L.³⁶

Mouse models with PRMT1-null B cells obtained with the Cre-LoxP system showed impaired B cell development and function in a T cell-independent but not T cell-dependent manner.³⁷ Furthermore, immunization with protein plus adjuvant or influenza virus infection resulted in impaired germinal center (GC)-related humoral immune responses, including the generation of antibody-secreting cells, in these mouse models.³⁸ A defect in PRMT1 activity is reportedly associated with the regulation of FOXO1 or PI3K,³⁹ which is essential for isotype switching and differentiation into antibody-secreting cells and subsequent GC formation.⁴⁰ In the present study, the serum levels of all Ag-specific immunoglobulins, including IgM, IgG and its subtypes, and IgE, were significantly higher in the WT mice than in the PRMT1-haploinsufficient mice. Whether this impaired Ag-specific immunoglobulin production is due to defects in PRMT1-mediated B cell differentiation and isotype switching and whether impaired PRMT1 function in B cells influences HDM-induced AR development and severity in mice remain unclear, and these topics should be further investigated using a mouse model with tissue-specific depletion of PRMT1.

The airway epithelium, which responds to external environmental factors, links the innate and adaptive immune systems through the release of cytokines and chemokines.⁴¹ TSLP, IL-25, and IL-33 are representative cytokines of epithelial-derived alarmins.⁴¹ A recent study showed that IL-25, IL-33 and TSLP are mainly produced and secreted by epithelial cells in response to cell damage, pathogen recognition or allergen exposure.^{41, 42} These epithelial-derived cytokines mediate various pathophysiological responses of allergic reactions by initiating Th2 cell and ILC2 responses, which results in the production of cytokines such as IL-4, IL-5, and IL-13.⁴¹⁻⁴⁵ Our results showed that HDM and IL-4 upregulated TSLP, IL-25, and IL-33 expression in nasal

epithelial cells in a PRMT1-dependent manner. In fact, the cytokine levels in NAL fluids were reduced in the PRMT1-haploinsufficient or AMI-1-treated mice with HDM-induced AR, and the levels of Th2 cytokines (IL-4, IL-5, and IL-13) in NAL fluids and IgE in serum were also lower in these mice. Accordingly, PRMT1 likely contributes to AR development by initiating the epithelial production of TSLP, IL-25, and IL-33 in response to allergen and IL-4 and subsequently inducing Th2 immunity.

PRMT1 is an asymmetric arginine methyltransferase and the H4R3me2as modification catalyzed by PRMT1 is a typical marker of active chromatin. TSLP, IL-25, and IL-33 are epithelial-derived cytokines, which are involved in allergic diseases by inducing type 2 responses. In this study, we demonstrated that PRMT1 mediates expression of TSLP, IL-25, and IL-33 genes in nasal epithelial cells under HDM and rIL-4 treatment. Since the PRMT1-mediated histone modification of H4R3me2as is associated with transcriptional activation of various genes,⁴⁶ it is of great interest to understand the mechanism by which PRMT1 regulates the epithelial-derived cytokine expressions. Musiani *et al.* reported that PRMT1 phosphorylated by DNA-PK is recruited to chromatin and then methylates H4R3 at the promoter of the senescence-associated secretory phenotype (SASP) gene, which expression is transcriptionally regulated by NF- κ B.⁴⁷ In addition, PRMT1 can directly methylate the RelA subunit of NF- κ B to form a cellular complex with it. This process leads to transcriptional regulation of target genes by manipulating the affinity between NF- κ B and the target genes in response to TNF- α .⁴⁸ It is also known that the gene expression of TSLP, IL-25, and IL-33 is regulated by the activation of NF- κ B.⁴⁹⁻⁵³ Further studies are needed to determine whether PRMT1 regulates gene expression of the epithelial-

421 derived cytokines via direct modification of histone at the target promoter regions or regulation
422 of NF- κ B activity.

423
424 In conclusion, PRMT1 is highly expressed in nasal epithelial cells, particularly in the nucleus, of
425 hosts with AR. Allergen and Th2 cytokines, such as IL-4, appear to cooperate to upregulate
426 PRMT1 expression. PRMT1 contributes to AR development by regulating the production of
427 epithelial cytokines, such as TSLP, IL-25, and IL-33, in response to allergens and IL-4, which
428 results in the promotion of differentiation into Th2 cells, IgE production and eosinophil
429 recruitment. The administration of the pan PRMT inhibitor AMI-1 alleviates the severity of
430 HDM-induced AR in mice, which suggests that PRMT1 might be a new therapeutic target for
431 AR. A new PRMT1-specific inhibitor that can be clinically applicable for AR patients thus needs
432 to be developed.

433 **Acknowledgments**

434 We thank to Prof. Ji-Hwan Ryu in Yonsei University College of Medicine for his kind advice.

References

1. Tan R, Cvetkovski B, Kritikos V, Price D, Yan K, Smith P, et al. Identifying the hidden burden of allergic rhinitis (AR) in community pharmacy: a global phenomenon. *Asthma Res Pract* 2017; 3:8.
2. Shin JH, Roh D, Lee DH, Kim SW, Kim SW, Cho JH, et al. Allergic rhinitis and rhinosinusitis synergistically compromise the mental health and health-related quality of life of Korean adults: A nationwide population-based survey. *PLoS One* 2018; 13:e0191115.
3. Zhang X, Lan F, Zhang Y, Zhang L. Chinese Herbal Medicine to Treat Allergic Rhinitis: Evidence From a Meta-Analysis. *Allergy Asthma Immunol Res* 2018; 10:34-42.
4. Brescia G, Marioni G, Franchella S, Ramacciotti G, Pendolino AL, Callegaro F, et al. Post-operative steroid treatment for eosinophilic-type sinonasal polyposis. *Acta Otolaryngol* 2015; 135:1200-4.
5. Naqvi M, Choudhry S, Tsai HJ, Thyne S, Navarro D, Nazario S, et al. Association between IgE levels and asthma severity among African American, Mexican, and Puerto Rican patients with asthma. *J Allergy Clin Immunol* 2007; 120:137-43.
6. Iberg AN, Espejo A, Cheng D, Kim D, Michaud-Levesque J, Richard S, et al. Arginine methylation of the histone H3 tail impedes effector binding. *J Biol Chem* 2008; 283:3006-10.
7. Chen Y, Xu X, Sheng M, Zhang X, Gu Q, Zheng Z. PRMT-1 and DDAHs-induced ADMA upregulation is involved in ROS- and RAS-mediated diabetic retinopathy. *Exp Eye Res* 2009; 89:1028-34.

- 458 8. Bedford MT, Clarke SG. Protein arginine methylation in mammals: who, what, and why.
459 Mol Cell 2009; 33:1-13.
- 460 9. Bedford MT, Richard S. Arginine methylation an emerging regulator of protein function.
461 Mol Cell 2005; 18:263-72.
- 462 10. Yang Y, Bedford MT. Protein arginine methyltransferases and cancer. Nat Rev Cancer
463 2013; 13:37-50.
- 464 11. Tang J, Kao PN, Herschman HR. Protein-arginine methyltransferase I, the predominant
465 protein-arginine methyltransferase in cells, interacts with and is regulated by interleukin
466 enhancer-binding factor 3. J Biol Chem 2000; 275:19866-76.
- 467 12. Poulard C, Corbo L, Le Romancer M. Protein arginine methylation/demethylation and
468 cancer. Oncotarget 2016; 7:67532-50.
- 469 13. Nicholson TB, Chen T, Richard S. The physiological and pathophysiological role of
470 PRMT1-mediated protein arginine methylation. Pharmacol Res 2009; 60:466-74.
- 471 14. Sun Q, Liu L, Wang H, Mandal J, Khan P, Hostettler KE, et al. Constitutive high
472 expression of protein arginine methyltransferase 1 in asthmatic airway smooth muscle
473 cells is caused by reduced microRNA-19a expression and leads to enhanced remodeling.
474 J Allergy Clin Immunol 2017; 140:510-24 e3.
- 475 15. Sun Q, Liu L, Roth M, Tian J, He Q, Zhong B, et al. PRMT1 Upregulated by Epithelial
476 Proinflammatory Cytokines Participates in COX2 Expression in Fibroblasts and Chronic
477 Antigen-Induced Pulmonary Inflammation. J Immunol 2015; 195:298-306.
- 478 16. Sun Q, Yang X, Zhong B, Jiao F, Li C, Li D, et al. Upregulated protein arginine
479 methyltransferase 1 by IL-4 increases eotaxin-1 expression in airway epithelial cells and
480 participates in antigen-induced pulmonary inflammation in rats. J Immunol 2012;

188:3506-12.

17. Meyerholz DK, Griffin MA, Castilow EM, Varga SM. Comparison of histochemical methods for murine eosinophil detection in an RSV vaccine-enhanced inflammation model. *Toxicol Pathol* 2009; 37:249-55.
18. Yu Z, Chen T, Hebert J, Li E, Richard S. A mouse PRMT1 null allele defines an essential role for arginine methylation in genome maintenance and cell proliferation. *Mol Cell Biol* 2009; 29:2982-96.
19. Galli SJ, Tsai M. IgE and mast cells in allergic disease. *Nat Med* 2012; 18:693-704.
20. Renauld JC. New insights into the role of cytokines in asthma. *J Clin Pathol* 2001; 54:577-89.
21. Hams E, Bermingham R, Fallon PG. Macrophage and Innate Lymphoid Cell Interplay in the Genesis of Fibrosis. *Front Immunol* 2015; 6:597.
22. Shin SH, Ye MK. Th2 responses elicited by nasal epithelial cells exposed to house dust mite extract. *Clin Exp Otorhinolaryngol* 2009; 2:175-80.
23. Jacquet A. The role of the house dust mite-induced innate immunity in development of allergic response. *Int Arch Allergy Immunol* 2011; 155:95-105.
24. Lloyd CM. Dust mites' dirty dealings in the lung. *Nat Med* 2009; 15:366-7.
25. Altan B, Yokobori T, Ide M, Mochiki E, Toyomasu Y, Kogure N, et al. Nuclear PRMT1 expression is associated with poor prognosis and chemosensitivity in gastric cancer patients. *Gastric Cancer* 2016; 19:789-97.
26. Mathioudaki K, Papadokostopoulou A, Scorilas A, Xynopoulos D, Agnanti N, Talieri M. The PRMT1 gene expression pattern in colon cancer. *Br J Cancer* 2008; 99:2094-9.
27. Mathioudaki K, Scorilas A, Ardavanis A, Lymberi P, Tsiambas E, Devetzi M, et al.

- 504 Clinical evaluation of PRMT1 gene expression in breast cancer. *Tumour Biol* 2011;
505 32:575-82.
- 506 28. Zakrzewicz D, Zakrzewicz A, Didiasova M, Korencak M, Kosanovic D, Schermuly RT,
507 et al. Elevated protein arginine methyltransferase 1 expression regulates fibroblast
508 motility in pulmonary fibrosis. *Biochim Biophys Acta* 2015; 1852:2678-88.
- 509 29. Choi JH, Jang AR, Kim DI, Park MJ, Lim SK, Kim MS, et al. PRMT1 mediates
510 RANKL-induced osteoclastogenesis and contributes to bone loss in ovariectomized mice.
511 *Exp Mol Med* 2018; 50:111.
- 512 30. Lim SK, Jeong YW, Kim DI, Park MJ, Choi JH, Kim SU, et al. Activation of PRMT1 and
513 PRMT5 mediates hypoxia- and ischemia-induced apoptosis in human lung epithelial cells
514 and the lung of miniature pigs: the role of p38 and JNK mitogen-activated protein kinases.
515 *Biochem Biophys Res Commun* 2013; 440:707-13.
- 516 31. Yang IV, Richards A, Davidson EJ, Stevens AD, Kolakowski CA, Martin RJ, et al. The
517 Nasal Methylome: A Key to Understanding Allergic Asthma. *Am J Respir Crit Care Med*
518 2017; 195:829-31.
- 519 32. Poole A, Urbanek C, Eng C, Schageman J, Jacobson S, O'Connor BP, et al. Dissecting
520 childhood asthma with nasal transcriptomics distinguishes subphenotypes of disease. *J*
521 *Allergy Clin Immunol* 2014; 133:670-8 e12.
- 522 33. Stefanowicz D, Hackett TL, Garmaroudi FS, Gunther OP, Neumann S, Sutanto EN, et al.
523 DNA methylation profiles of airway epithelial cells and PBMCs from healthy, atopic and
524 asthmatic children. *PLoS One* 2012; 7:e44213.
- 525 34. Herrmann F, Fackelmayer FO. Nucleo-cytoplasmic shuttling of protein arginine
526 methyltransferase 1 (PRMT1) requires enzymatic activity. *Genes Cells* 2009; 14:309-17.

35. Tamura K, Ishikawa G, Yoshie M, Ohneda W, Nakai A, Takeshita T, et al. Glibenclamide inhibits NLRP3 inflammasome-mediated IL-1 β secretion in human trophoblasts. *J Pharmacol Sci* 2017; 135:89-95.
36. Hata K, Mizuguchi J. Arginine methylation regulates antibody responses through modulating cell division and isotype switching in B cells. *Microbiol Immunol* 2013; 57:185-92.
37. Hata K, Yanase N, Sudo K, Kiyonari H, Mukumoto Y, Mizuguchi J, et al. Differential regulation of T-cell dependent and T-cell independent antibody responses through arginine methyltransferase PRMT1 in vivo. *FEBS Lett* 2016; 590:1200-10.
38. Infantino S, Light A, O'Donnell K, Bryant V, Avery DT, Elliott M, et al. Arginine methylation catalyzed by PRMT1 is required for B cell activation and differentiation. *Nat Commun* 2017; 8:891.
39. Yamagata K, Daitoku H, Takahashi Y, Namiki K, Hisatake K, Kako K, et al. Arginine methylation of FOXO transcription factors inhibits their phosphorylation by Akt. *Mol Cell* 2008; 32:221-31.
40. Omori SA, Cato MH, Anzelon-Mills A, Puri KD, Shapiro-Shelef M, Calame K, et al. Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling. *Immunity* 2006; 25:545-57.
41. Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. *Nat Med* 2015; 21:677-87.
42. Masters SL, Latz E, O'Neill LA. The inflammasome in atherosclerosis and type 2 diabetes. *Sci Transl Med* 2011; 3:81ps17.
43. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking

- interleukin-1 in a broad spectrum of diseases. *Nat Rev Drug Discov* 2012; 11:633-52.
44. Iyer SS, Pulskens WP, Sadler JJ, Butter LM, Teske GJ, Ulland TK, et al. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. *Proc Natl Acad Sci U S A* 2009; 106:20388-93.
 45. Sun XF, Zhang H. NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. *Histol Histopathol* 2007; 22:1387-98.
 46. Gao Y, Zhao Y, Zhang J, Lu Y, Liu X, Geng P, et al. The dual function of PRMT1 in modulating epithelial-mesenchymal transition and cellular senescence in breast cancer cells through regulation of ZEB1. *Sci Rep* 2016; 6:19874.
 47. Musiani D, Giambruno R, Massignani E, Ippolito MR, Maniaci M, Jammula S, et al. PRMT1 Is Recruited via DNA-PK to Chromatin Where It Sustains the Senescence-Associated Secretory Phenotype in Response to Cisplatin. *Cell Rep* 2020; 30:1208-22 e9.
 48. Reintjes A, Fuchs JE, Kremser L, Lindner HH, Liedl KR, Huber LA, et al. Asymmetric arginine dimethylation of RelA provides a repressive mark to modulate TNFalpha/NF-kappaB response. *Proc Natl Acad Sci U S A* 2016; 113:4326-31.
 49. Kang J, Song J, Shen S, Li B, Yang X, Chen M. Diisononyl phthalate aggravates allergic dermatitis by activation of NF-kB. *Oncotarget* 2016; 7:85472-82.
 50. Lee HC, Ziegler SF. Inducible expression of the proallergic cytokine thymic stromal lymphopoietin in airway epithelial cells is controlled by NFkappaB. *Proc Natl Acad Sci U S A* 2007; 104:914-9.
 51. Valizadeh A, Khosravi A, Zadeh LJ, Parizad EG. Role of IL-25 in Immunity. *J Clin Diagn Res* 2015; 9:OE01-4.
 52. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an

- 573 interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and
574 induces T helper type 2-associated cytokines. *Immunity* 2005; 23:479-90.
- 575 53. Kobori A, Yagi Y, Imaeda H, Ban H, Bamba S, Tsujikawa T, et al. Interleukin-33
576 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. *J*
577 *Gastroenterol* 2010; 45:999-1007.

Figure legends

FIG 1. Gene expression of PRMTs in the nasal mucosa of healthy patients and patients with AR. **A-D**, The gene expression of PRMT1, PRMT3, PRMT4 and PRMT5 in the nasal mucosa of non-AR control and AR patients was measured by RT-PCR. The horizontal bars indicate the means. *, $P < 0.05$

FIG 2. PRMT1 expression in the nasal mucosa of HDM-induced AR mice. **A-D**, The gene expression of PRMT1, 3, 4 and 5 in the nasal mucosa of control and AR-induced mice was measured by RT-PCR. **E**, Immunohistochemistry was performed to determine the cellular localization of PRMT1 expression in the nasal mucosa of mice. **F and H**, The density of nucleus expressed PRMT1 was measured using ImageJ program, and the results are expressed as the means $\pm$ SDs. **G**, The PRMT1 protein levels in the nasal tissues of mice ($n=5$) with or without AR were determined by Western blotting. **H**, Relative protein levels were obtained by dividing the density of PRMT1 by that of β -actin and the results are also expressed as the means $\pm$ SDs. *, $P < 0.05$, **, $P < 0.01$, ***, $P < 0.001$. Bar = 20 μ m.

FIG 3. Goblet cell metaplasia, eosinophil infiltration and serum levels of Ag-specific immunoglobulins in WT and *PRMT1*^{+/-} mice with HDM-induced AR. **A**, Goblet cell metaplasia and eosinophil infiltration were evaluated in AB/PAS- or Sirius red-stained sections of WT and *PRMT1*^{+/-} mice with and without AR, respectively. **B and C**, AB/PAS- and Sirius red-positive cell counts were obtained as described in the Materials and Methods, and the results are expressed as the means $\pm$ SDs. **D-I**, Levels of IgE, IgM, IgG, and IgG subtypes specific to


HDM in the mouse serum were measured by ELISA. The horizontal bars indicate the means. *, $P < 0.05$, ***, $P < 0.001$. Bar = 20 μm .


FIG 4. Th2- and epithelial-derived cytokine production in NAL fluids of AR-induced WT and PRMT1^{+/-} mice. A-F, NAL fluids were obtained by flushing the nasal cavity with 700 μl of PBS. A-C, The levels of Th2 cytokines, including IL-4, IL-5, and IL-13, were measured by ELISA. D-F, The levels of epithelial-derived cytokines, including TSLP, IL-25 and IL-33, were measured by ELISA. The horizontal bars indicate the means. *, $P < 0.05$, ***, $P < 0.001$.


FIG 5. PRMT1 expression and localization in nasal epithelial cells in response to HDM and IL-4. A-J, RPMI 2650 cells were treated with HDM (100 $\mu\text{g/ml}$) and/or rIL-4 (10 ng/ml). A, The gene expression of PRMT1 after 8 h of treatment was analyzed by RT-PCR. B and C, The PRMT1 protein levels after 24 h of treatment were confirmed by Western blotting and quantified. D and E, The localization of PRMT1 expression was identified and quantified by immunofluorescent confocal microscopic analysis. F, The ADMA formation after 72 h of treatment were examined by Western blotting. G, The expression of phosphorylated forms of ERK, JNK, and p38 was detected by Western blotting. H-K, Cells were pretreated with MAP kinase inhibitors, such as PD98059, SP600125, and SB203580, for 2 h and subsequently incubated with HDM and rIL-4 for an additional 24 h. H and I, The PRMT1 protein levels were confirmed by Western blotting and quantified. J and K, The PRMT1 localization was determined and quantified by confocal microscopic analysis. The results are expressed as the means $\pm$ SDs. ***, $P < 0.001$. Values with different letters are significantly ($P < 0.05$) different, as determined by ANOVA with Duncan's multiple range test.


FIG 6. PRMT1 inhibition reduces TSLP, IL-25, and IL-33 expression in nasal epithelial cells in response to HDM and IL-4. RPMI 2650 cells (**A**) and A549 cells (**B**) were transfected with scramble or PRMT1 siRNA and then treated with HDM (100 µg/ml) and rIL-4 (10 ng/ml) for 12 h. **A and B**, The gene expression of TSLP, IL-25, IL-33, and PRMT1 was measured by RT-PCR. **C and D**, Primary HNE cells were pretreated with AMI-1 (20 µg/ml) for 1 h and then treated with HDM and rIL-4 for an additional 12 or 72 h. **C**, The gene expression of TSLP, IL-25, and IL-33 was measured by RT-PCR. **D**, The TSLP levels in culture supernatants were detected by ELISA. The results are expressed as the means ± SDs. *, $P < 0.05$, **, $P < 0.01$, ***, $P < 0.001$.


FIG 7. AMI-1 administration attenuates AR severity in mice. **A**, Schematic representation of the experimental protocol. **B**, Representative images of Sirius red- and H&E-stained nasal tissue sections. **C and D**, AB/PAS- and Sirius red-positive cell counts were obtained as described in the Materials and Methods, and the results are expressed as the means ± SDs. **E**, The serum levels of HDM-specific IgE, IgM, and IgG were measured by ELISA. **F**, The levels of Th2 cytokines, including IL-4, IL-5, and IL-13, were measured by ELISA. **G**, The levels of epithelial-derived cytokines, including TSLP, IL-25 and IL-33, were measured by ELISA. The horizontal bars indicate the means. *, $P < 0.05$, **, $P < 0.01$, ***, $P < 0.001$. Bar = 20 µm.





















A**B****C****D****E****F****G**

○ PBS/PBS □ HDM/HDM ■ HDM/HDM + AMI-1